Fundraising Fox
🦊/People
Sign in

Carol Suh

Investor

Partner at ARCH Venture Partners

San Francisco Bay Area

Writes $50K – $150M checks · typically $25M

Find your path to Carol

160 people in our graph share verified history with Carol — schools, employers, funds. One of them is your warm intro.

Erin MooreunlockedCarol: together at GlaxoSmithKline (2014)
Carol: together at GlaxoSmithKline
Carol: together at Trinity Partners
×9Carol: together at ARCH Venture Partners

About

Carol Suh is a Partner at ARCH Venture Partners focused on early-stage biotechnology investments. Her background spans both investing and operations, including co-founding Orbital Therapeutics, an RNA medicines company acquired for $1.5B in 2025, and co-founding Neumora Therapeutics, which went public on NASDAQ. She has also invested in HI-Bio, a clinical-stage immunology company acquired by Biogen in 2024, and serves as a founding board member of the Complex Disorders Alliance.

Contact· self-published, not guessed

Experience

  1. ARCH Venture PartnersPartnercurrent2018 — present
  2. NeumoraCo-Founder and Chief Strategy Officer2019 — 2026San Francisco Bay Area
  3. Orbital TherapeuticsCo-founder, Board Member2022 — 2025
  4. HIBioBoard Member2021 — 2024
  5. Magenta TherapeuticsBusiness Development and Corporate Strategy Associate; Launch Fellow2016 — 2017Cambridge, MA
  6. Trinity PartnersSenior Associate Consultant2015 — 2016Waltham, MA
  7. GlaxoSmithKlineR&D Strategy; Innovation Fellow2014Greater Boston

Investments

Per curated public sources.

Colleagues at ARCH Venture Partners

Ari Nowacek
Partner at ARCH Venture Partners
Ari Nowacek, M.D, Ph.D.
Partner at ARCH Venture Partners
Axel Bouchon
Venture Partner at ARCH Venture Partners
Axel Bouchon, Ph.D.
Venture Partner at ARCH Venture Partners
Brian Cuneo
Senior Partner at ARCH Venture Partners
Clinton Bybee
Co-founder & Managing Director, Emeritus at ARCH Venture Partners
Corey Ritter
Partner at ARCH Venture Partners
David Moore
Senior Partner at ARCH Venture Partners

Network4

Ari Nowacek
Partner at ARCH Venture Partners
Corey Ritter
Partner at ARCH Venture Partners
Inca Dieterich
Venture Partner at ARCH Venture Partners
Jake Bauer
Venture Partner at ARCH Venture Partners

Investors connected to Carol in public investor directories — a warm-intro map.

Frequently asked questions

Who is Carol Suh?
Carol Suh is a Partner at ARCH Venture Partners focused on early-stage biotechnology investments. Her background spans both investing and operations, including co-founding Orbital Therapeutics, an RNA medicines company acquired for $1.5B in 2025, and co-founding Neumora Therapeutics, which went public on NASDAQ. She has also invested in HI-Bio, a clinical-stage immunology company acquired by Biogen in 2024, and serves as a founding board member of the Complex Disorders Alliance.
Where does Carol Suh work?
Carol Suh is Partner at ARCH Venture Partners.
What check size does Carol Suh write?
Carol Suh typically writes checks of $50K – $150M.
What companies has Carol Suh invested in?
Investments tracked here include HI-Bio, Orbital Therapeutics.
Where did Carol Suh go to school?
Carol Suh studied at Stanford University Graduate School of Business (Master of Business Administration - MBA); Yale University (Master of Philosophy (M.Phil.)); Harvard University (Bachelor of Arts (B.A.)).

Founder mafias

Magenta Therapeutics mafia2

Also came through, then founded or led a company.

Dima VremenkoMass Spectrometry Co-opFounded Inkbox

Same school

Shared employers